V-A WHOLESALER DEMONSTRATION PROJECT CONTRACTS AWARDED
Executive Summary
V-A WHOLESALER DEMONSTRATION PROJECT CONTRACTS AWARDED to Harris Wholesale, Alco Health Services and McKesson in September and will take effect on Nov. 1. The contracts will test the use of wholesalers as "prime vendors" for nearly $ 60 mil. in pharmaceuticals used by a total of 33 Department of Veterans Affairs medical centers across the U.S. The arrangement covers all drugs used for inpatients at the medical centers or dispensed to outpatients at affiliated clinics, but not drugs dispensed at outlying, free-standing V-A facilities. The contracts are for one year with an option to renew for another two years. The demonstrations could serve as an entree for wholesalers into the V-A program, which historically has handled drug distribution itself. V-A will evaluate the project by comparing the cost and ease of obtaining products for the 33 test sites versus 33 other V-A centers serving as control sites. Harris won two contracts -- one covering the Southwest region worth an estimated $ 11 mil. in annual V-A sales, and another covering the Northeast worth $ 14 mil. Alco's contract covers 10 centers in the Midwest and will steer an estimated $ 22 mil. to the company. McKesson will handle $ 10 mil. in business at five centers in the Northwest. According to the companies, any pre-existing V-A contracts negotiated with manufacturers for price discounts will be honored under the demonstration projects. McKesson said it plans to install its "Econolink" computerized order-entry system in the centers covered by its contract. With Econolink, a V-A employee will place an order electronically; the products selected are immediately reserved from McKesson's inventory and delivered the next day.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth